Literature DB >> 17429418

Metabolic risk factors and renal disease.

J R Sowers1.   

Abstract

Accumulating evidence supports that components of the metabolic syndrome coexist with both albuminuria and chronic kidney disease (CKD). The article by Tomaszewski et al. indicates that this interrelation exists in young obese men before overt renal or cardiovascular disease and also suggests that early treatment of hypertension is especially compelling to prevent the evolution of renal hyperfiltration to CKD.

Entities:  

Mesh:

Year:  2007        PMID: 17429418     DOI: 10.1038/sj.ki.5002006

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  38 in total

Review 1.  Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease.

Authors:  Jun Ren; Lakshmi Pulakat; Adam Whaley-Connell; James R Sowers
Journal:  J Mol Med (Berl)       Date:  2010-08-20       Impact factor: 4.599

2.  Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin.

Authors:  Adam Whaley-Connell; Javad Habibi; Zachary Panfili; Melvin R Hayden; Sarika Bagree; Ravi Nistala; Safwan Hyder; Bennett Krueger; Vincent Demarco; Lakshmi Pulakat; Carlos M Ferrario; Alan Parrish; James R Sowers
Journal:  Am J Nephrol       Date:  2011-06-29       Impact factor: 3.754

3.  Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors.

Authors:  Ankur Jindal; Stephen Brietzke; James R Sowers
Journal:  Cardiorenal Med       Date:  2012-11-24       Impact factor: 2.041

4.  Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort.

Authors:  Eliecer Coto; Beatriz Tavira; Juan Gómez; Salvador Tranche; Carmen Díaz Corte
Journal:  Cardiorenal Med       Date:  2014-04-23       Impact factor: 2.041

5.  Poor accordance to a DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension.

Authors:  Tanushree Banerjee; Deidra C Crews; Delphine S Tuot; Meda E Pavkov; Nilka Rios Burrows; Austin G Stack; Rajiv Saran; Jennifer Bragg-Gresham; Neil R Powe
Journal:  Kidney Int       Date:  2019-03-04       Impact factor: 10.612

6.  [The role of aldosterone in hypertension].

Authors:  Oliver Vonend; Ivo Quack; Lars Christian Rump
Journal:  Wien Klin Wochenschr       Date:  2010-02       Impact factor: 1.704

Review 7.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

8.  Metabolic syndrome and chronic kidney disease.

Authors:  D Bhowmik; S C Tiwari
Journal:  Indian J Nephrol       Date:  2008-01

9.  Proteinuria and decreased body mass index as a significant risk factor in developing end-stage renal disease.

Authors:  Kunitoshi Iseki; Kaori Tokashiki; Chiho Iseki; Kentaro Kohagura; Kozen Kinjo; Shuichi Takishita
Journal:  Clin Exp Nephrol       Date:  2008-06-27       Impact factor: 2.801

10.  Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

Authors:  G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard
Journal:  Br J Pharmacol       Date:  2016-04-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.